Douglas Miehm
Stock Analyst at RBC Capital
(3.94)
# 1,850
Out of 4,630 analysts
407
Total ratings
50.6%
Success rate
5.4%
Average return
Main Sectors:
Stocks Rated by Douglas Miehm
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LGND Ligand Pharmaceuticals | Reiterated: Buy | $345 | $293.15 | +17.69% | 21 | Aug 9, 2026 | |
| AUPH Aurinia Pharmaceuticals | Maintained: Hold | $15 → $16 | $15.85 | +0.95% | 44 | Aug 7, 2026 | |
| TSX: GUD Knight Therapeutics Inc. | Maintained: Buy | $9.50 → $11.00 | $9.76 | +12.70% | 28 | Aug 7, 2026 | |
| TSX: DR Medical Facilities Corporation | Maintained: Hold | $19.00 | $15.18 | +25.16% | 47 | Aug 7, 2026 | |
| MNKD MannKind | Maintained: Hold | $4.75 | $4.11 | +15.57% | 10 | Aug 6, 2026 | |
| PCRX Pacira BioSciences | Maintained: Hold | $24 → $25 | $25.02 | -0.08% | 6 | Aug 5, 2026 | |
| TSX: APTX Apotex Health Corp. | Maintained: Buy | $43.00 | $37.38 | +15.03% | 2 | Aug 4, 2026 | |
| TSX: BHC Bausch Health Companies Inc. | Reiterated: Hold | $12.61 | $8.70 | +44.89% | 104 | Jul 30, 2026 | |
| BLCO Bausch + Lomb | Maintained: Buy | $21 | $16.78 | +25.15% | 38 | Jul 30, 2026 | |
| TSX: DHT.UN DRI Healthcare Trust | Maintained: Buy | $21.00 | $17.63 | +19.12% | 41 | May 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $7.00 | $4.15 | +68.67% | 22 | May 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $7.85 | $15.89 | -50.58% | 1 | Mar 19, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $2.5 → $3.5 | $0.8025 | +336.14% | 30 | Nov 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $18 → $19 | $4.57 | n/a | 2 | Oct 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | €22.00 | €112.60 | n/a | 3 | Jun 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $1 | $6.65 | n/a | 6 | Aug 4, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $3 → $2.3 | $0.000001 | n/a | 2 | Nov 6, 2013 |
Ligand Pharmaceuticals
Aug 9, 2026
Reiterated: Buy
Price Target: $345
Current: $293.15
Upside: +17.69%
Aurinia Pharmaceuticals
Aug 7, 2026
Maintained: Hold
Price Target: $15 → $16
Current: $15.85
Upside: +0.95%
Knight Therapeutics Inc.
Aug 7, 2026
Maintained: Buy
Price Target: $9.50 → $11.00
Current: $9.76
Upside: +12.70%
Medical Facilities Corporation
Aug 7, 2026
Maintained: Hold
Price Target: $19.00
Current: $15.18
Upside: +25.16%
MannKind
Aug 6, 2026
Maintained: Hold
Price Target: $4.75
Current: $4.11
Upside: +15.57%
Pacira BioSciences
Aug 5, 2026
Maintained: Hold
Price Target: $24 → $25
Current: $25.02
Upside: -0.08%
Apotex Health Corp.
Aug 4, 2026
Maintained: Buy
Price Target: $43.00
Current: $37.38
Upside: +15.03%
Bausch Health Companies Inc.
Jul 30, 2026
Reiterated: Hold
Price Target: $12.61
Current: $8.70
Upside: +44.89%
Bausch + Lomb
Jul 30, 2026
Maintained: Buy
Price Target: $21
Current: $16.78
Upside: +25.15%
DRI Healthcare Trust
May 15, 2026
Maintained: Buy
Price Target: $21.00
Current: $17.63
Upside: +19.12%
May 10, 2026
Reiterated: Buy
Price Target: $7.00
Current: $4.15
Upside: +68.67%
Mar 19, 2026
Maintained: Buy
Price Target: $7.85
Current: $15.89
Upside: -50.58%
Nov 19, 2025
Maintained: Buy
Price Target: $2.5 → $3.5
Current: $0.8025
Upside: +336.14%
Oct 8, 2021
Reiterated: Hold
Price Target: $18 → $19
Current: $4.57
Upside: n/a
Jun 23, 2021
Maintained: Buy
Price Target: €22.00
Current: €112.60
Upside: n/a
Aug 4, 2016
Reiterated: Hold
Price Target: $1
Current: $6.65
Upside: n/a
Nov 6, 2013
Rated: Hold
Price Target: $3 → $2.3
Current: $0.000001
Upside: n/a